July 30, 2012
Celgene K.K. announced on July 25 that it has initiated a PII clinical trial in Japan for its hematopoietic malignant tumor treatment Revlimid (lenalidomide hydrate) in treatment-naïve patients with multiple myeloma. The trial will evaluate the safety and efficacy of...read more